Related references
Note: Only part of the references are listed.First-Line Cetuximab Monotherapy in KRAS/NRAS/BRAF Mutation-Negative Colorectal Cancer Patients
Vladimir M. Moiseyenko et al.
CLINICAL DRUG INVESTIGATION (2018)
Smoking, B Vitamins, and Lung Cancer: The Chicken or the Egg Causality Dilemma Reply
Theodore M. Brasky et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Combined BRAF, EGFR, and MEK Inhibition in Patients with &ITBRAF&ITV600E-Mutant Colorectal Cancer
Ryan B. Corcoran et al.
CANCER DISCOVERY (2018)
Multicenter phase II study of infusional 5-fluorouracil (5-FU), leucovorin, and oxaliplatin, plus biweekly cetuximab as first-line treatment in patients with metastatic colorectal cancer (CELINE trial)
Masanori Kotake et al.
ONCOLOGY LETTERS (2017)
Description of the health problem
Nicola Huxley et al.
HEALTH TECHNOLOGY ASSESSMENT (2017)
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer A Randomized Clinical Trial
Alan P. Venook et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
BRAF Mutations as Predictive Biomarker for Response to Anti-EGFR Monoclonal Antibodies
Emilie M. J. van Brummelen et al.
ONCOLOGIST (2017)
Exploring the effect of primary tumor sidedness on therapeutic efficacy across treatment lines in patients with metastatic colorectal cancer: analysis of FIRE-3 (AIOKRK0306)
Dominik Paul Modest et al.
ONCOTARGET (2017)
Exclusion of Kaposi Sarcoma From Analysis of Cancer Burden Reply
Christina Fitzmaurice et al.
JAMA ONCOLOGY (2017)
Cost-effectiveness of cetuximab and panitumumab for chemotherapy-refractory metastatic colorectal cancer
Adriana Camargo Carvalho et al.
PLOS ONE (2017)
Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines
S. Rosello et al.
ANNALS OF ONCOLOGY (2017)
Management of adverse events during treatment of gastrointestinal cancers with epidermal growth factor inhibitors
Ralf-Dieter Hofheinz et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2017)
Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study
Tormod Kyrre Guren et al.
BRITISH JOURNAL OF CANCER (2017)
Cost-effectiveness of cetuximab for colorectal cancer
Taehwan Park et al.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2016)
Management of oral and gastrointestinal mucosal injury: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-upaEuro
D. E. Peterson et al.
ANNALS OF ONCOLOGY (2015)
Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and RAS Mutations in Colorectal Cancer
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature
David L. Chan et al.
PLOS ONE (2015)
Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials
M. J. Sorich et al.
ANNALS OF ONCOLOGY (2015)
Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
E. Van Cutsem et al.
ANNALS OF ONCOLOGY (2014)
Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features
E. Missiaglia et al.
ANNALS OF ONCOLOGY (2014)
Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study
Timothy J. Price et al.
LANCET ONCOLOGY (2014)
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
Volker Heinemann et al.
LANCET ONCOLOGY (2014)
Role of cetuximab in first-line treatment of metastatic colorectal cancer
Miguel Jhonatan Sotelo et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Use of Early Tumor Shrinkage to Predict Long-Term Outcome in Metastatic Colorectal Cancer Treated With Cetuximab
Hubert Piessevaux et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-VII Study
Kjell Magne Tveit et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study
Robert Pirker et al.
LANCET ONCOLOGY (2012)
Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion
K. Potthoff et al.
ANNALS OF ONCOLOGY (2011)
Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
Timothy S. Maughan et al.
LANCET (2011)
Management of Skin Toxicity Associated with Cetuximab Treatment in Combination with Chemotherapy or Radiotherapy
Carmine Pinto et al.
ONCOLOGIST (2011)
Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities
Mario E. Lacouture et al.
SUPPORTIVE CARE IN CANCER (2011)
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
Wendy De Roock et al.
LANCET ONCOLOGY (2010)
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Eric Van Cutsem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
The biological properties of cetuximab
Bruno Vincenzi et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2008)
Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1,3-galactose
Christine H. Chung et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
Christos S. Karapetis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Cetuximab for the treatment of colorectal cancer
Derek J. Jonker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
D Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Share Paper
